NovAliX, a Contract Research Organization (CRO) specializing in drug discovery, has announced a strategic alliance with Bruker, a leading provider of scientific instruments. The partnership involves Bruker taking a minority ownership stake in NovAliX.
 
The investment aims to leverage NovAliX’s expertise in structural biology, biophysics, and pharmacology to develop innovative analytical solutions that enhance drug discovery success. By combining Bruker’s advanced analytical capabilities with NovAliX’s expert services, the partnership seeks to accelerate the incubation, deployment, and support of cutting-edge biophysical methods.
 
Stephan Jenn, President of NovAliX, said: “Bruker is at the forefront of technology serving the life sciences and focuses on the best ways to deploy technology for the advancement of science. For over 20 years, NovAliX has independently developed an unrivaled research engine, combining our biophysics legacy with the therapeutic expertise of researchers from Janssen, Sanofi, and Galapagos, some of whom have won awards for discovering new drugs. Now, our alliance with Bruker marks a crucial step in further enhancing the research capacity we offer for our biopharmaceutical customers’ therapeutic projects.”
 
Falko Busse, President of Bruker BioSpin, explained: “We recognized NovAliX as a leading drug discovery CRO with an unrivaled technological and biophysical focus, thus presenting an opportunity to establish a strategic alliance with Bruker. Additionally, we were convinced by the IBRB concept as a novel approach to ensuring progress and access to the characterization technologies essential for the successful research and development of new therapies.”
 
A key component of the partnership is the establishment of the Biophysics Institute for Biomedical Research (IBRB). This unique collaboration between a top-tier academic institution, a leading instrument provider, and NovAliX’s scientific team will foster scientific innovation and support discovery and development projects.
 
Denis Zeyer, CEO of NovAliX, said: “IBRB will significantly contribute to the ongoing transformation of this industry. By fostering interaction between stakeholders and organizing access to shared knowledge through the joint use of major facilities, IBRB will enable new therapeutic innovation to mature effectively.”